Our vision is to become the leading ophthalmic company in regenerative biologic therapies.
Our mission is to develop and deliver high-quality and innovative regenerative wound healing solutions to eyecare providers and their patients.
Bio-Tissue serves as an operating entity engaged in the procurement, processing, storage and distribution of cryopreserved human amniotic membrane (AmnioGraft® and PROKERA®) for transplantation and research uses. In addition, Bio-Tissue has retained patent rights to process, preserve, and distribute cryopreserved human amniotic membrane for ocular surface reconstruction.
Bio-Tissue is registered with the US Food and Drug Administration (FDA) as:
- A Tissue Bank (recover, screen, test, package, process, label, store and distribute tissue)
- A Medical Device Manufacturer and Specification Developer
Bio-Tissue adheres to the FDA's tissue and medical device guidelines. Bio-Tissue is also licensed to operate as a tissue bank by the Department of Health in the State of New York and California.